



**Division de gastro-entérologie**  
**Division of Gastroenterology**

**Dr. A. Bitton**

Directeur  
Director

**Dr. W. Afif**

Directeur de site, HGM  
Site Director, MGH

**Dr. V. Baffis**

**Dr. A. Barkun**

Directeur endoscopie  
thérapeutique et directeur  
de l'évaluation de la qualité,  
CUSM

Director, Bilio-Pancreatic  
Endoscopy and Chief Quality  
Officer, MUHC

**Dr. T. Bessissow**

**Dr. P. Cleland**

**Dr. M. Deschênes**

Directeur de l'hépatologie, CUSM  
Hepatology Director, MUHC

**Dr. C. A. Fallone**

President, Association des médecins  
du département, CUSM  
Chair, Departmental Association  
of Physicians, MUHC

**Dr. P. Ghali**

Directeur de site, HRV  
Site Director, RVH

**Dr. S. Mayrand**

Directeur, Finances  
Financial Director

**Dr. S. Mishkin**

**Dr. P. Lakatos**

Directeur, Centre MII, CUSM  
Director, MUHC IBD Centre

**Dr. J. Parent**

**Dr. G. Sebastiani**

**Dr. E. Seidman**

Titulaire de la chaire en MII  
et directeur de la recherche  
McGill Chair in IBD and Director  
of G.I. Research

**Dr. M. Sewitch**

Directrice de la recherche en santé  
des populations, CUSM  
Director, Population Health Research  
MUHC

**Dr. C. Soulellis**

Directeur de programme  
de résidence, Université McGill  
Residency Program Director  
McGill University

**Dr. P.L. Szego**

**Dr. K. Waschke**

Directeur de l'endoscopie, CUSM  
Endoscopy Director, MUHC

**Dr. G. Wild**

**Dr. P. Wong**

Hôpital général de Montréal  
Montreal General Hospital  
C7-200 - 1650 Cedar  
Montréal QC H3G 1A4  
Canada

Tel 514 934-8308

Fax 514 934-8531

Hôpital Royal Victoria, site Glen  
Royal Victoria Hospital, Glen site  
D05.7150 - 1001 boul Décarie  
Montréal QC H4A 3J1  
CANADA

Tel 514 843-1616

Fax 514 843-1421

[cusc.ca](http://cusc.ca) [muhc.ca](http://muhc.ca)

Response to reviewers

23/09/2019

**Subrata Ghosh**

Editor-in-Chief

**Jin-Zhou Tang**

Science Editor, Editorial Office

Dear Editors,

Please find attached our detailed responses to the reviewers' comments:

Title:

**Disease monitoring strategies in IBD: what do we mean by 'tight control'?**

Authors:

Lorant Gonczi, Talat Bessissow, Peter L. Lakatos

Reviewer #1, Number ID: unknown; review received via email.

**This review is well written and is aiming at detailed analysis of recent evidences on treat-to-target approach to target composite clinical and endoscopic therapeutic endpoints. For this aim, close monitoring of objective markers of inflammation (clinical, endoscopic and biomarkers) to direct therapeutic decisions until these goals are reached.**

**According to this reviewing process there are a lot of successful scientific evidences which support the benefit of 'treat-to-target' and 'tight control' strategies. However, there remain many questions how this approaches are validated using composite definition of endoscopic items and biomarkers as authors have pointed out. These undefined items require resolution by prospective clinical trials which are fitted to real world scenario of treatment courses as is pointed out by authors.**



**In this review it is required to mention on monitoring process and that TDM should have a great role to analyze treatment failure such as loss of response at a proper timing. When using new biologics in appropriate way early diagnosis of LOR of the first biologic and quick switching to another biologic or to a new drug is warranted. For this switching how TDM should be used? Please give a comment on this issue.**

Thank you for the comments, we included a short section and an additional table regarding the role of TDM in LOR.

Reviewer #2, Number ID: 00036225

Thank you for the comments. We included some of the reviewer's suggestions and corrected all orthographic mistakes/typing errors.

Reviewer #3, Number ID: 03373346

No comments were raised.

Reviewer #4, Number ID: 00503405

We corrected the mentioned typing errors.

We further modified and language edited the manuscript, which has been reviewed by a native English-speaking co-author.

Sincerely,

Dr. Lorant Gonczi and Dr. Peter Lakatos on behalf of all the authors,

Peter LAKATOS, MD, DSc, FEBG, AGAF  
Associate Editor of World Journal Of Gastroenteorlogy



Director of IBD Centre, Professor of Medicine,  
McGill University, MUHC, Montreal General Hospital,  
1650 Ave. Cedar, D16.173.1, Montreal, QC, H3G 1A4  
Tel: +-1-514-9341934 x ext 45567  
Fax: +1-514-934-4452  
Tel: +1-514-4317994  
e-mail: [Peter.Lakatos@muhc.mcgill.ca](mailto:Peter.Lakatos@muhc.mcgill.ca)  
e-mail: [peter.lakatos@mcgill.ca](mailto:peter.lakatos@mcgill.ca)